2023-505632-35-00
进行中（未招募）
3 期
Open-Label, Randomized, Multicenter, Multi-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to Less Than 18 Years of Age with Relapsing-Remitting Multiple Sclerosis with Optional Open-Label Extension (CONNECT)
概览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 37
- 试验地点
- 2
- 主要终点
- The primary endpoint of Part 1 of the study is the proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Week 96.
概览
简要总结
The main objectives of Part 1 are as follows: • To evaluate the safety, tolerability, and efficacy on the disease course of BG00012 (dimethyl fumarate) in subjects with RRMS, as compared with a disease modifying treatment. • To assess health outcomes and evolution of disability
The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed week 96 in Part 1 of Study 109MS306.
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •Must have a body weight of ≥30 kg.
- •Must have a diagnosis of RRMS (consensus definition for pediatric RRMS [Krupp 2013]).
- •Must be ambulatory with a baseline EDSS score between 0 and 5.5, inclusive.
- •Must have experienced at least 1 relapse within the last 12 months prior to Day 1 or at least 2 relapses within the last 24 months prior to Day 1, with a prior brain MRI demonstrating lesions consistent with MS, or evidence of Gd enhancing lesions of the brain on an MRI performed within the 6 weeks prior to Day
- •Must be neurologically stable, with no evidence of relapse within 50 days prior to Day 1 and no evidence of corticosteroid treatment within 30 days prior to Day
- •Subjects of childbearing potential who are sexually active must be willing to practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their final dose of study treatment.
- •Part 2: Subjects who have completed Week96 in Part 1
排除标准
- •Primary progressive, secondary progressive, or progressive relapsing MS (as defined by [Lublin and Reingold 1996]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses but are distinguished from relapsing remitting subjects by the lack of clinically stable periods or clinical improvement.
- •Key Treatment history - Any previous treatment with Fumaderm (fumaricacid esters) or BG00012
- •Prior treatment with any of the following: total lymphoid irradiation, cladribine, Tcell or Tcell receptor vaccination, any therapeutic monoclonal antibody, with the exception of rituximab or natalizumab.
- •Prior treatment with any of the following medications within the 12 months prior to Day 1: mitoxantrone, cyclophosphamide, rituximab.
- •Prior treatment with any of the following medications or procedures within 6 months prior to Day 1: fingolimod; teriflunomide; natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; laquinimod; intravenous (IV) immunoglobulin; plasmapheresis or cytapheresis
- •Treatment with any of the following medications within 30 days prior to Day 1: steroids (IV or oral corticosteroid treatment, including agents that may not act through the corticosteroid pathway [e.g.low dose naltrexone]), 4aminopyridine or related products (except subjects on a stable dose of controlled release fampridine for 3 months)
- •Part 2: Any significant changes in medical history occurring after enrollment in Part 1
- •Subjects who could not tolerate BG00012 in Part 1
- •Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease, lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
- •History of premalignant or malignant disease. Subjects with basal cell carcinoma that has been completely excised prior to screening will remain eligible.
结局指标
主要结局
The primary endpoint of Part 1 of the study is the proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Week 96.
The primary endpoint of Part 1 of the study is the proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Week 96.
The primary endpoint of the Part 2 is the incidence of adverse events, serious adverse events and discontinuations of BG00012 due to an adverse event
The primary endpoint of the Part 2 is the incidence of adverse events, serious adverse events and discontinuations of BG00012 due to an adverse event
次要结局
- Part 1: Number of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Weeks 24 and 96
- Proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Weeks 24 and 48
- Proportion of participants free of new MRI activity (new MRI activity includes: Gd enhancing MRI lesion on brain MRI scans; new T2 MRI lesions on brain MRI scans and newly enlarging LRI lesions on brain MRI scans) at Weeks 24, 48, and 96
- Time to first relapse up to week 96
- Proportion of participants who do not experience relapse up to Week 96
- Annualized relapse rate at Weeks 48 and 96
- Number of participants that experience Adverse Events (AEs) and serious adverse events (SAEs) Including prospective and followup of flushing, nausea, abdominal pain and diarrhea up to Week 96
- Fatigue as measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale scores up to Week 96
- Change from baseline to Week 96 in the Expanded Disability Status Scale (EDSS) score up to Week 96.
- Vital signs, electrocardiograms (ECGs) and changes in clinical laboratory data, including monitoring of liver function, renal function, hematologic, and coagulation parameters up to Week 96.
- Part 2: include annualized relapse rate; EDSS; cognition as measured by BVMT-R, SDMT, and school progression query; vital signs; ECGs; clinical laboratory data; changes from baseline in height, weight, and bone age; and Tanner stage.
研究者
Clinical Trials Information Desk
Scientific
Biogen Idec Research Limited
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsNCT07261631Novartis Pharmaceuticals180
招募中
不适用
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid TumorsNCT07310134Nanjing Zenshine Pharmaceuticals80
尚未招募
不适用
68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07310355Chengdu StarRay Therapeutics Co., Ltd49
招募中
1 期
Study of CM383 in Healthy SubjectsNCT07292688Keymed Biosciences Co.Ltd30
招募中
1/2 期
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)2023-505925-15-00Institut Gustave Roussy150